|
| Friday, 5 April 2019, 18:00 HKT/SGT | |
| |  | |
Source: A*STAR | |
|
|
|
SINGAPORE, Apr 5, 2019 - (ACN Newswire) - It is with deep regret that the Agency for Science, Technology and Research (A*STAR) announces the passing of Dr Sydney Brenner, Honorary Singapore Citizen, and A*STAR Senior Fellow, early this morning.
 | | Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, and A*Star Senior Fellow, has died. |
 | | Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow and Honorary Singapore Citizen, has died. |
Dr Brenner was conferred the Nobel Prize in Physiology or Medicine in 2002 for his pioneering work in the field of molecular biology. For over six decades, he had shaped modern biology and understanding of the genetic code.
His dedication and commitment to Singapore over the past three and a half decades have also left an indelible mark on our nation's R&D journey. Dr Brenner challenged all of us to think ahead for the future, and spurred the establishment of Singapore's first major research institute for science, the Institute of Molecular and Cell Biology (IMCB), in 1985. This was a crucial stepping stone for Singapore's push into the biomedical sciences. Through his support, the A*STAR Graduate Academy was established to help Singapore build its own pipeline of young scientists and engineers.
"A giant in the field of molecular biology, Sydney played a key role in shaping Singapore's research and development landscape from its early years. His deep contributions in biomedical sciences have helped put Singapore on the global map. Today, Singapore is an emerging biomedical hub. Sydney will be remembered by the scientific community and beyond. My thoughts and prayers are with his family." - Ms Chan Lai Fung, Chairman, A*STAR
"Dr Brenner's contributions have shaped Singapore's R&D journey, from biomedical research to talent development. He has been an inspiration to those he has worked closely with over the years, as well as those who have admired him from afar. No doubt, he will continue to be a source of inspiration for generations of scientists to come. Our thoughts are with Dr Brenner's family." - Mr Frederick Chew, Chief Executive Officer, A*STAR
More information on Dr Brenner's achievements can be found in Annex A.
ANNEX A: Dr Sydney Brenner's Achievements
Dr Sydney Brenner was a renowned pioneer in molecular biology. His many achievements included deciphering how the triplet codon works, the discovery of messenger RNA, and the use of the worm, C. elegans, as a model system for human disease. This culminated in his being conferred the Nobel Prize in Physiology or Medicine in 2002.
Dr Brenner's dedication and commitment to Singapore has also contributed to policies and initiatives that have left an indelible mark on the nation's R&D journey. Since his first visit in 1983, he had played a key role in building the biomedical sciences in Singapore. Dr Brenner challenged the nation to think ahead for the future, which led to the establishment of Singapore's first major research institute for science, the Institute of Molecular and Cell Biology or IMCB, in 1985. This proved to be a turning point and crucial stepping stone for the country's foray into the biomedical sciences.
Over the past three and a half decades, Dr Brenner guided Singapore on its R&D journey, including his recent capacity as the Scientific Advisor to former Chairman A*STAR Lim Chuan Poh. For his contributions, Dr Brenner received many accolades, including the Distinguished Friends of Singapore in 2000, Honorary Citizen in 2003 and the National Science and Technology Medal in 2006.
Dr Brenner had a strong passion in ensuring that young people receive a good education in Science. Through his support, the A*STAR Graduate Academy was established to help Singapore build its own pipeline of young scientists and engineers, many of whom now contribute in our research institutes, universities, polytechnics, hospitals and local companies. This has helped raise the standing and reputation of Singapore as one of the leading global centres for science, research and education.
Last November, a book entitled "10-on-10: The Chronicles of Evolution" was launched as tribute to Dr Brenner's extraordinary vision and legacy. The book was written by 24 renowned scientists and is a compilation of a series of lectures on evolution, that was the brainchild of Dr Brenner.
Photos of Sydney Brenner.zip (16.1 MB) https://bit.ly/2YRuM1K
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, it collaborates with its partners in both the public and private sectors to benefit society.
A*STAR's R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, please visit www.a-star.edu.sg.
For further media queries, please contact:
Ms Gladys Chung
A*STAR Corporate Communications
Email: gladys_chung@hq.a-star.edu.sg
Tel/Mobile: +65 6826 6348 / +65 9680 2284
Mr Robin Chan
A*STAR Corporate Communications
Email: robin_chan@hq.a-star.edu.sg
Tel/Mobile: +65 6517 7940 / +65 9759 2284
Topic: Press release summary
Source: A*STAR
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| A*STAR |
| Dec 6, 2022 14:00 HKT/SGT |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| Sept 30, 2021 16:00 HKT/SGT |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
| July 31, 2020 08:00 HKT/SGT |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| July 24, 2020 17:00 HKT/SGT |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| Oct 22, 2019 04:00 HKT/SGT |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| June 28, 2019 08:00 HKT/SGT |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| Jan 21, 2019 13:00 HKT/SGT |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
| July 13, 2018 10:00 HKT/SGT |
|
Scientists Discover the Tuberal Nucleus' Role in Controlling Appetite and Body Weight |
| More news >> |
 |
|
|
|
